Sanofi (SNY) Restructuring Costs (2009 - 2016)
Sanofi (SNY) posted Restructuring Costs of -$551.5 million for Q1 2016, up 36.71% sequentially from -$871.4 million in Q4 2015, and down 38.28% YoY from -$893.6 million in Q2 2015.
Sanofi (SNY) Restructuring Costs (2009 - 2016) Analysis & Trends
Sanofi has reported Restructuring Costs for 8 years, with the latest figure at -$551.5 million in Q1 2016.
- Quarterly Restructuring Costs fell 38.28% year-over-year to -$551.5 million in Q1 2016, while the trailing twelve-month figure through Mar 2016 was -$1.5 billion (down 165.37% YoY) and the FY2025 annual result came in at $1.3 billion, down 11.2% from the prior year.
- Restructuring Costs climbed to -$551.5 million in Q1 2016 per SNY's latest filing, from -$871.4 million in the prior quarter.
- Over five years, Restructuring Costs peaked at $1.5 billion in Q4 2012 and troughed at -$871.4 million in Q4 2015.
- A 5-year average of -$28.5 million and a median of $69.9 million in 2014 frame the typical range for Restructuring Costs.
- The sharpest annual moves came in 2012 and 2015: Restructuring Costs jumped 171.99% in 2012, then sank 670.67% in 2015.
- Over 5 years, Restructuring Costs stood at $1.5 billion in 2012, then tumbled by 127.87% to -$412.4 million in 2013, then slipped by 22.43% to -$504.9 million in 2014, then sank by 72.58% to -$871.4 million in 2015, then surged by 36.71% to -$551.5 million in 2016.
- According to Business Quant data, Restructuring Costs over the past three periods registered -$551.5 million, -$871.4 million, and -$64.5 million for Q1 2016, Q4 2015, and Q3 2015 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2016 | -551.51 Mn |
| Dec 31, 2015 | -871.41 Mn |
| Sep 30, 2015 | -64.51 Mn |
| Jun 30, 2015 | -30.94 Mn |
| Mar 31, 2015 | -398.83 Mn |
| Dec 31, 2014 | -504.93 Mn |
| Sep 30, 2014 | 216.35 Mn |
| Jun 30, 2014 | 115.24 Mn |
| Mar 31, 2014 | 69.89 Mn |
| Dec 31, 2013 | -412.41 Mn |
| Sep 30, 2013 | 94.08 Mn |
| Jun 30, 2013 | 137.10 Mn |
| Mar 31, 2013 | 71.30 Mn |
| Dec 31, 2012 | 1.48 Bn |
| Sep 30, 2012 | 71.28 Mn |
| Jun 30, 2012 | 209.45 Mn |
| Mar 31, 2012 | -114.08 Mn |
| Dec 31, 2011 | 1.77 Bn |
| Sep 30, 2011 | -99.02 Mn |
| Jun 30, 2011 | -496.28 Mn |